Prasugrel is a thienopyridine antiplatelet drug developed by Eli Lilly and first pharmaceutical Co., Ltd., a Japanese pharmaceutical company. It is a precursor drug. It forms active molecules in the liver after metabolism by cytochrome P450, and binds with platelet P2Y12 receptor to exert antiplatelet aggregation activity. Clinical studies have proved that 60 mg dose of clopidogrel has better anticoagulant effect than 300 mg standard dose and 600 mg increased dose of clopidogrel, which can reduce the comprehensive risk of heart attack, stroke and death due to heart disease by 20%, and has fast effect, good curative effect, good drug resistance and bioavailability, and low toxicity. Prasugrel also has stronger performance than clopidogrel in stable angina pectoris and acute coronary syndrome interventional surgery, but the stronger the antiplatelet effect is, the easier it is to cause bleeding. Now the key problem is how to identify the high-risk patients of thrombosis and the high-risk groups of bleeding, so that prasugrel and clopidogrel can be used differently in the two high-risk groups, which can reduce coronary thrombosis and avoid major bleeding.
Manufacturing
